Sangamo Biosciences (SGMO): A Huge Biotech Investment Opportunity

In addition to Celgene (CELG), I recommend Sangamo Biosciences for a biotech/pharma investment with huge profit potential. Sangamo has developed zinc finger protein (ZFP) technology, a transcription factor that controls the expression of DNA in the nucleus of the cell. The most advanced ZFP Therapeutic™ development programs are in Phase I clinical trials for patients with diabetic neuropathy and peripheral artery disease. Other therapeutic programs deal with macular degeneration, ischemic heart disease, congestive heart failure, neuropathic pain, and infectious diseases. The potential is huge in many other areas. For example, Sangamo is working with Dow AgroSciences , a division of Dow Chemical Company, to use ZFP technology for plant cells to explore agricultural applications. We are still very early in the development of ZFP. Get in now and enjoy the ride!

tags: investing  invest  stocks  health  

links: digg this    del.icio.us    technorati    reddit